EXOSENS COMPLETES THE ACQUISITION OF LR TECH, LEADER IN SPECTRORADIOMETER BASED SOLUTIONS
EXOSENS COMPLETES THE ACQUISITION OF LR TECH, LEADER IN SPECTRORADIOMETER BASED SOLUTIONS PRESS RELEASEMÉRIGNAC, FRANCE AND QUEBEC, CANADA – SEPTEMBER, 2nd 2024 Exosens announces the completion of the acquisition of…
EXOSENS FINALISE L’ACQUISITION DE LR TECH, LEADER DES SOLUTIONS DE SPECTRORADIOMÉTRIE
EXOSENS FINALISE L'ACQUISITION DE LR TECH, LEADER DES SOLUTIONS DE SPECTRORADIOMÉTRIE COMMUNIQUÉ DE PRESSEMÉRIGNAC, FRANCE ET QUÉBEC, CANADA - 2 SEPTEMBRE 2024 Exosens annonce la finalisation de l'acquisition de la…
CORRECTION – MiddleGround Capital launches Voluntary Public Takeover Offer for STEMMER IMAGING AG
In a release issued under the same headline earlier today by MiddleGround Capital, please note in the second bullet of the subheadline, the date of the Acceptance Period has been…
Hepsor AS Subsidiary to Build a Wooden Apartment Building in Central Tallinn
Hepsor V7 OÜ, a subsidiary of Hepsor AS, acquired a property in the heart of Tallinn, at Võistluse 7, where it is planned to build a unique environmentally friendly wooden…
Sword Group : 1st step in German-speaking Switzerland
The Group acquired INCOR, a company based in Bern! INCOR is a Bern-based company specialising in Digital Transformation. INCOR has developed digital know-how on long-term projects mainly dedicated to the…
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis In the HERCULES study, tolebrutinib…
CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament qui a permis d’observer une réduction de l’accumulation du handicap chez des personnes avec une sclérose en plaques…
Le tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament ayant permis d’observer une réduction de l’accumulation du handicap chez des personnes…
Sword Group : 1er pas en Suisse Alémanique
Le Groupe procède à l’acquisition de INCOR, société basée à Berne ! INCOR, est une société basée à Berne et spécialisée dans la Transformation Digitale.INCOR a développé des savoir-faire digitaux…
Form 8.5 (EPT/RI) – musicMagpie Plc
FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY…
VGP NV: Voting Rights and Denominator
Press ReleaseRegulated InformationAntwerp, 2 September 2024– 7.00 a.m. CET In application of Article 15 of the Law of May 2, 2007 on the disclosure of major shareholdings in issuers whose…